Double Dhamaka! Dr. Lal PathLabs Ltd Announces Bonus Shares & Interim Dividend
DSIJ Intelligence-1 / 27 Oct 2025/ Categories: Bonus and Spilt Shares, Dividend, Mindshare, Trending
The company has a market cap of Rs 26,000 crore with a PE of 51x, an ROE of 24 per cent and an ROCE of 29 per cent.
Dr. Lal PathLabs Limited informed that a meeting of the Board of Directors is scheduled to be held on Friday, October 31, 2025, to inter alia:
- Consider and approve unaudited (standalone & consolidated) financial results of the company for the quarter and half year ended September 30, 2025.
- Consider declaration of 2nd interim dividend, if any, on the equity shares of the company for the Financial Year 2025-26.
- Consider issuance of bonus shares in accordance with the applicable provisions and subject to the approval of the shareholders of the company.
Dr. Lal PathLabs Limited (DLPL) is one of India's foremost consumer healthcare brands specialising in diagnostic services, boasting the nation's largest diagnostics chain with a pan-India presence and over 75 years of experience. DLPL provides an extensive range of diagnostic and related healthcare tests and services, from basic preventative packages like SwasthFit to highly advanced investigations such as Comprehensive Genomic Profiling and Myeloid testing. These services are vital for core testing, patient diagnosis, and the prevention, monitoring, and treatment of various health conditions, serving individual patients, hospitals, healthcare providers and corporate clients across the country.
Also Read DSIJ Blog: Comparing India’s Defence Stocks: HAL vs BEL vs BDL – Who Could Perform Better?
The company has a market cap of Rs 26,000 crore with a PE of 51x, an ROE of 24 per cent and an ROCE of 29 per cent. The stock is up by 39.2 per cent from its 52-week low of Rs 2,295.10 per share.
Disclaimer: The article is for informational purposes only and not investment advice.